Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis

Xi Guang Li, Paul Haluska, Yaw Huei Hsiang, Ajit K. Bharti, Donald W. Kufe, Leroy-Fong Liu, Eric H. Rubin

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Camptothecins are antineoplastic drugs that specifically target the enzyme DNA topoisomerase I. Prior work has identified a human topoisomerase I mutation, F361S, that confers resistance to camptothecin. We now demonstrate that substitutions in the 361-364 region can alter DNA cleavage/ligation by the enzyme. The defective catalysis exhibited by certain mutants likely relates to an impaired interaction with DNA, since these enzymes are more sensitive to the inhibitory effects of DNA binding ligands. Moreover, studies with peptides and fusion proteins suggest that the 361-364 region may bind DNA directly. The finding that the 361-364 region is involved in both enzyme catalysis and camptothecin resistance suggests that this region is part of the active site of human topoisomerase I and that camptothecin may interact with the enzyme at this site.

Original languageEnglish
Pages (from-to)1019-1027
Number of pages9
JournalBiochemical Pharmacology
Volume53
Issue number7
DOIs
Publication statusPublished - Apr 4 1997
Externally publishedYes

Fingerprint

Camptothecin
Type I DNA Topoisomerase
Catalysis
Amino Acids
Enzymes
DNA
DNA Cleavage
Antineoplastic Agents
Ligation
Catalytic Domain
Substitution reactions
Fusion reactions
Ligands
Peptides
Mutation
Proteins

Keywords

  • camptothecin
  • DNA binding
  • DNA cleavage
  • drug resistance
  • enzyme mutations
  • topoisomerase

ASJC Scopus subject areas

  • Pharmacology

Cite this

Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis. / Li, Xi Guang; Haluska, Paul; Hsiang, Yaw Huei; Bharti, Ajit K.; Kufe, Donald W.; Liu, Leroy-Fong; Rubin, Eric H.

In: Biochemical Pharmacology, Vol. 53, No. 7, 04.04.1997, p. 1019-1027.

Research output: Contribution to journalArticle

Li, Xi Guang ; Haluska, Paul ; Hsiang, Yaw Huei ; Bharti, Ajit K. ; Kufe, Donald W. ; Liu, Leroy-Fong ; Rubin, Eric H. / Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis. In: Biochemical Pharmacology. 1997 ; Vol. 53, No. 7. pp. 1019-1027.
@article{c75c566e87e344e885c9779bd0cb44f6,
title = "Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis",
abstract = "Camptothecins are antineoplastic drugs that specifically target the enzyme DNA topoisomerase I. Prior work has identified a human topoisomerase I mutation, F361S, that confers resistance to camptothecin. We now demonstrate that substitutions in the 361-364 region can alter DNA cleavage/ligation by the enzyme. The defective catalysis exhibited by certain mutants likely relates to an impaired interaction with DNA, since these enzymes are more sensitive to the inhibitory effects of DNA binding ligands. Moreover, studies with peptides and fusion proteins suggest that the 361-364 region may bind DNA directly. The finding that the 361-364 region is involved in both enzyme catalysis and camptothecin resistance suggests that this region is part of the active site of human topoisomerase I and that camptothecin may interact with the enzyme at this site.",
keywords = "camptothecin, DNA binding, DNA cleavage, drug resistance, enzyme mutations, topoisomerase",
author = "Li, {Xi Guang} and Paul Haluska and Hsiang, {Yaw Huei} and Bharti, {Ajit K.} and Kufe, {Donald W.} and Leroy-Fong Liu and Rubin, {Eric H.}",
year = "1997",
month = "4",
day = "4",
doi = "10.1016/S0006-2952(96)00899-4",
language = "English",
volume = "53",
pages = "1019--1027",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis

AU - Li, Xi Guang

AU - Haluska, Paul

AU - Hsiang, Yaw Huei

AU - Bharti, Ajit K.

AU - Kufe, Donald W.

AU - Liu, Leroy-Fong

AU - Rubin, Eric H.

PY - 1997/4/4

Y1 - 1997/4/4

N2 - Camptothecins are antineoplastic drugs that specifically target the enzyme DNA topoisomerase I. Prior work has identified a human topoisomerase I mutation, F361S, that confers resistance to camptothecin. We now demonstrate that substitutions in the 361-364 region can alter DNA cleavage/ligation by the enzyme. The defective catalysis exhibited by certain mutants likely relates to an impaired interaction with DNA, since these enzymes are more sensitive to the inhibitory effects of DNA binding ligands. Moreover, studies with peptides and fusion proteins suggest that the 361-364 region may bind DNA directly. The finding that the 361-364 region is involved in both enzyme catalysis and camptothecin resistance suggests that this region is part of the active site of human topoisomerase I and that camptothecin may interact with the enzyme at this site.

AB - Camptothecins are antineoplastic drugs that specifically target the enzyme DNA topoisomerase I. Prior work has identified a human topoisomerase I mutation, F361S, that confers resistance to camptothecin. We now demonstrate that substitutions in the 361-364 region can alter DNA cleavage/ligation by the enzyme. The defective catalysis exhibited by certain mutants likely relates to an impaired interaction with DNA, since these enzymes are more sensitive to the inhibitory effects of DNA binding ligands. Moreover, studies with peptides and fusion proteins suggest that the 361-364 region may bind DNA directly. The finding that the 361-364 region is involved in both enzyme catalysis and camptothecin resistance suggests that this region is part of the active site of human topoisomerase I and that camptothecin may interact with the enzyme at this site.

KW - camptothecin

KW - DNA binding

KW - DNA cleavage

KW - drug resistance

KW - enzyme mutations

KW - topoisomerase

UR - http://www.scopus.com/inward/record.url?scp=0030972846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030972846&partnerID=8YFLogxK

U2 - 10.1016/S0006-2952(96)00899-4

DO - 10.1016/S0006-2952(96)00899-4

M3 - Article

VL - 53

SP - 1019

EP - 1027

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 7

ER -